...
首页> 外文期刊>Journal of Lipid Research >Relative roles of the LDL receptor, the LDL receptor-like protein, and hepatic lipase in chylomicron remnant removal by the liver.
【24h】

Relative roles of the LDL receptor, the LDL receptor-like protein, and hepatic lipase in chylomicron remnant removal by the liver.

机译:LDL受体,LDL受体样蛋白和肝脂肪酶在肝脏清除乳糜微粒残留中的相对作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Studies were carried out in mice utilizing inhibitors of several cell surface molecules to evaluate their relative roles in chylomicron remnant removal. Anti-LDL receptor antibody inhibited approximately 45% of rapid remnant removal from plasma, prolonged their half life (63 s to 115 s) and reduced hepatic uptake by 45%. Receptor-associated protein (RAP) (1 mg/mouse), a high affinity inhibitor of the LDL receptor-related protein (LRP) and a low affinity inhibitor of the LDL receptor decreased remnant removal approximately 55%, prolonged the half life from 63 s to 230 s, and reduced hepatic uptake by 70%. RAP, but not anti-LDL receptor antibody, inhibited splenic uptake. With both injected together, an incremental effect was seen; plasma removal decreased 60%, T1/2 increased to 290 s, and hepatic uptake decreased by 80%. Thus, it is likely that virtually all of the very rapid removal of remnants from the plasma by the liver requires the presence of at least one of these members of the LDL receptor family. Anti-hepatic lipase antibody caused a small but significant delay in remnant removal from plasma and a larger decrease in hepatic uptake (22.5%). It doubled adrenal uptake. The anti-hepatic lipase antibody was not additive with either the anti-LDL receptor antibody or RAP. Anti-rat hepatic lipase antibody did not inhibit lipolysis by mouse hepatic lipase, suggesting that lipolysis is not the way hepatic lipase enhances remnant uptake. Hepatic lipase bound to remnants to a greater degree than it bound to other lipoproteins. Together these data suggest that hepatic lipase may serve as a binding site for chylomicron remnants, thereby enhancing their affinity for the liver surface, and thus removal by the proteins of the LDL receptor family. Other molecules may also play a role in removal from the circulation under conditions where the LDL receptor family receptors are absent or occupied.
机译:使用几种细胞表面分子的抑制剂在小鼠中进行了研究,以评估它们在乳糜微粒残留去除中的相对作用。抗LDL受体抗体抑制了大约45%的血浆快速残留清除,延长了其半衰期(63 s至115 s),并使肝脏吸收降低了45%。受体相关蛋白(RAP)(1 mg /小鼠),LDL受体相关蛋白(LRP)的高亲和力抑制剂和LDL受体的低亲和力抑制剂使残留清除率降低了约55%,从63延长了半衰期s至230 s,并减少了70%的肝吸收。 RAP抑制脾脏摄取,但不抑制抗LDL受体抗体。将两者注射在一起,可以看到渐进的效果。血浆去除率降低60%,T1 / 2升高至290 s,肝吸收降低80%。因此,实际上,肝脏从血浆中非常快速地去除残留物的所有可能都需要至少一种LDL受体家族成员的存在。抗肝脂肪酶抗体会导致血浆中残留物去除的延迟小而显着,而肝吸收率则有较大的下降(22.5%)。它使肾上腺摄取增加了一倍。抗肝脂肪酶抗体不能与抗LDL受体抗体或RAP叠加。抗大鼠肝脂肪酶抗体不能抑制小鼠肝脂肪酶的脂解作用,这表明脂解不是肝脂酶增强残余摄取的方式。肝脂肪酶与残基的结合程度大于与其他脂蛋白的结合程度。这些数据加在一起表明,肝脂肪酶可以作为乳糜微粒残余物的结合位点,从而增强它们对肝表面的亲和力,从而被LDL受体家族的蛋白质清除。在缺少或占据LDL受体家族受体的条件下,其他分子也可能在循环中发挥作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号